Thermo Fisher Scientific is showcasing new capabilities in AI-enabled research, clinical development, and advanced manufacturing at BIO International 2026. The company announced strategic investments and partnerships designed to help biopharma customers advance innovation, simplify complex workflows, and bring therapies to patients faster. These initiatives reinforce Thermo Fisher’s role as a provider of integrated solutions across the drug development lifecycle.
Pharma Services and Advanced Manufacturing
Thermo Fisher is expanding its global manufacturing capacity to support biologics, sterile fill-finish, oral solid dose manufacturing, and integrated device assembly. Recent investments include:
| Capability |
Details |
| Sterile Fill-Finish |
Expanded capacity for prefilled syringes, vials, cartridges, and autoinjectors, including a collaboration with SHL Medical at the Ridgefield, New Jersey site. |
| Oral Solid Dose (OSD) |
Advanced tableting technologies, additional laboratory capacity, and new packaging and serialization capabilities across global sites. |
| Biologics |
Added significant drug substance capacity in the U.S. and Switzerland. |
| Monoclonal Antibodies |
Launching new GMP manufacturing capabilities in Plainville, Mass., in the second half of 2026. |
| Bioprocess Design Centers |
Expanded network with new facilities in the U.S. and India, complementing existing centers in China, Korea, and Singapore. |
Clinical Research and Data Intelligence
The company is advancing clinical development through expanded digital capabilities and acquisitions. Thermo Fisher completed the acquisition of Clario Holdings Inc., adding endpoint data and evidence generation solutions that have supported approximately 70% of FDA and EMA novel drug approvals over the past decade. Strategic collaborations with HealthVerity and Datavant aim to advance real-world evidence and trial optimization. Additionally, AI-enabled analytics and workflow solutions are being deployed to improve clinical trial efficiency and decision-making.
AI-Enabled Research and Scientific Workflows
Thermo Fisher is leveraging strategic relationships with NVIDIA, OpenAI, TetraScience, and BenchSci to enhance AI-enabled scientific workflows. These partnerships help customers automate laboratory workflows, unify scientific data, and generate deeper insights. Through the Accelerator Drug Development program, the company supports emerging biotech companies in combining scientific expertise with AI-enabled workflows. Recent software acquisitions, including MSAID and Proteinaceous, strengthen the proteomics ecosystem by adding AI and machine learning capabilities for interpreting complex datasets.
Scientific Innovation and Enabling Technologies
New workflow innovations include the Applied Biosystems PowerFlex Thermal Cycler and the Gibco CTS Compleo Fill and Finish System. The company also unveiled the Gibco CTS DynaXS Single Use Bioreactor for scalable cell therapy manufacturing and launched the Gibco CHOvantage GS Cell Line Development Kit to streamline timelines and support scalable manufacturing.
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
